menu
    • menu

    Company profile for Immuron

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steato...
    Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmuronAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131
    Telephone
    Telephone
    +613 8892 4802
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immuron.com.au/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immuronltd/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ImmuronLtd?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immuron IMM-529 IND Approved By FDA
    Immuron IMM-529 IND Approved By FDA

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181195/37134/en/Immuron-IMM-529-IND-approved-by-FDA.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Immuron Announces Clinical Trial Update
    Immuron Announces Clinical Trial Update

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178196/37134/en/Immuron-Announces-Clinical-Trial-Update.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Immuron Q1 FY26 Yoy Growth
    Immuron Q1 FY26 Yoy Growth

    13 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/13/3165382/37134/en/Immuron-Q1-FY26-YoY-growth.html

    GLOBENEWSWIRE
    13 Oct 2025
    Share Share
    Immuron Submits IMM-529 IND To FDA
    Immuron Submits IMM-529 IND To FDA

    08 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/08/3163147/37134/en/Immuron-Submits-IMM-529-IND-to-FDA.html

    GLOBENEWSWIRE
    08 Oct 2025
    Share Share
    Immuron Letter To Shareholders – Projects Update
    Immuron Letter To Shareholders – Projects Update

    02 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160195/37134/en/Immuron-Letter-to-Shareholders-Projects-Update.html

    GLOBENEWSWIRE
    02 Oct 2025
    Share Share
    Immuron FY25 Global Sales Exceed Projection, up 49% on Prior Year
    Immuron FY25 Global Sales Exceed Projection, up 49% on Prior Year

    17 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/17/3117064/37134/en/Immuron-FY25-global-sales-exceed-projection-up-49-on-prior-year.html

    GLOBENEWSWIRE
    17 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search